EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,750,000 | +209.3% | 175,367 | +310.7% | 0.17% | +290.7% |
| Q2 2022 | $889,000 | -48.1% | 42,697 | -43.5% | 0.04% | -55.2% |
| Q1 2022 | $1,713,000 | -33.1% | 75,583 | -46.0% | 0.10% | +1.1% |
| Q4 2021 | $2,560,000 | +108.6% | 140,052 | +141.3% | 0.10% | +50.8% |
| Q3 2021 | $1,227,000 | -11.6% | 58,040 | -23.8% | 0.06% | +5.0% |
| Q2 2021 | $1,388,000 | +313.1% | 76,200 | +412.2% | 0.06% | +215.8% |
| Q1 2021 | $336,000 | +11.3% | 14,877 | +20.6% | 0.02% | -42.4% |
| Q3 2020 | $302,000 | +26.4% | 12,335 | +22.6% | 0.03% | -17.5% |
| Q2 2020 | $239,000 | -33.1% | 10,061 | -51.5% | 0.04% | -7.0% |
| Q1 2020 | $357,000 | -68.5% | 20,735 | -67.6% | 0.04% | -37.7% |
| Q3 2019 | $1,132,000 | +333.7% | 64,000 | +424.6% | 0.07% | +200.0% |
| Q2 2019 | $261,000 | -76.6% | 12,200 | -73.9% | 0.02% | -86.4% |
| Q1 2019 | $1,114,000 | +222.0% | 46,800 | +165.9% | 0.17% | +64.1% |
| Q4 2018 | $346,000 | – | 17,600 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |